Affinity Asset Advisors LLC Acquires 799,448 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Affinity Asset Advisors LLC grew its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 133.1% during the first quarter, Holdings Channel.com reports. The firm owned 1,400,000 shares of the company’s stock after acquiring an additional 799,448 shares during the period. Centessa Pharmaceuticals accounts for about 2.9% of Affinity Asset Advisors LLC’s portfolio, making the stock its 7th largest position. Affinity Asset Advisors LLC’s holdings in Centessa Pharmaceuticals were worth $55,608,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Millennium Management LLC boosted its holdings in Centessa Pharmaceuticals by 52.9% in the first quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock valued at $8,760,000 after acquiring an additional 210,737 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Centessa Pharmaceuticals during the first quarter worth $2,176,000. Geode Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 44.7% in the second quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock valued at $1,149,000 after purchasing an additional 26,994 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Centessa Pharmaceuticals by 155.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock worth $5,630,000 after acquiring an additional 260,702 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in Centessa Pharmaceuticals by 29.2% during the second quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock worth $1,291,000 after purchasing an additional 22,205 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on CNTA. Leerink Partners lowered Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their price target for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Wolfe Research lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Wells Fargo & Company cut Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $35.00 to $42.00 in a report on Monday, April 20th. Finally, Guggenheim downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 2nd. Four analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $41.33.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $40.50 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a fifty-two week low of $12.74 and a fifty-two week high of $40.56. The company’s 50 day moving average price is $40.14 and its two-hundred day moving average price is $33.69. The firm has a market capitalization of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). As a group, research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.